Get the Stockscreener App
11.23
2.46%
0.27
Cartesian Therapeutics Inc stock is traded at $11.23, with a volume of 84,145.
It is up +2.46% in the last 24 hours and down -7.80% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$10.96
Open:
$11.2
24h Volume:
84,145
Relative Volume:
1.31
Market Cap:
$292.00M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.2255
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
-0.88%
1M Performance:
-7.80%
6M Performance:
-41.63%
1Y Performance:
-16.01%
1-Day Range:
$10.95
$11.80
1-Week Range:
$10.49
$11.80
52-Week Range:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
11.23 | 293.30M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Measuring Cartesian Therapeutics Inc.’s beta against major indicesJuly 2025 Catalysts & Community Verified Swing Trade Signals - Newser
Cartesian Therapeutics Inc. stock trend forecastJuly 2025 Volume & Consistent Profit Trading Strategies - Newser
Cartesian Therapeutics Inc. Hits Price Floor — Bounce IncomingQuarterly Profit Review & AI Driven Price Predictions - beatles.ru
Published on: 2025-08-19 22:41:14 - Newser
Combining machine learning predictions for Cartesian Therapeutics Inc.Earnings Overview Report & Stock Market Timing Techniques - Newser
Real time scanner hits for Cartesian Therapeutics Inc. explainedQuarterly Portfolio Review & Weekly Hot Stock Watchlists - Newser
How to use a screener to detect Cartesian Therapeutics Inc. breakoutsTrade Volume Summary & Consistent Profit Alerts - Newser
How to escape a deep drawdown in Cartesian Therapeutics Inc.2025 AllTime Highs & Verified Short-Term Plans - Newser
Order flow analysis tools used on Cartesian Therapeutics Inc.Portfolio Risk Summary & Long-Term Growth Plans - Newser
Published on: 2025-08-19 02:57:11 - classian.co.kr
What’s next for Cartesian Therapeutics Inc. stock priceMarket Sentiment Report & Community Verified Trade Alerts - Newser
Is Cartesian Therapeutics Inc. stock ready for a breakoutMarket Performance Recap & Safe Entry Momentum Tips - Newser
Backtesting results for Cartesian Therapeutics Inc. trading strategies2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - Newser
Relative strength of Cartesian Therapeutics Inc. in sector analysisWeekly Market Report & High Yield Stock Recommendations - Newser
Exit strategy if you’re trapped in Cartesian Therapeutics Inc.July 2025 Review & High Conviction Investment Ideas - Newser
What recovery options are there for Cartesian Therapeutics Inc.Quarterly Portfolio Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Heatmap analysis for Cartesian Therapeutics Inc. and competitorsWeekly Trade Review & Safe Entry Trade Signal Reports - Newser
Is it too late to sell Cartesian Therapeutics Inc.Quarterly Profit Report & Risk Controlled Swing Alerts - Newser
Tick level data insight on Cartesian Therapeutics Inc. volatility2025 Price Targets & Low Risk Growth Stock Ideas - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityPortfolio Performance Report & Advanced Swing Trade Entry Alerts - Newser
Real time alert setup for Cartesian Therapeutics Inc. performanceLayoff News & Free Weekly Chart Analysis and Trade Guides - Newser
Cartesian Therapeutics Inc. Stock Fails to Break Resistance Traders ReactJuly 2025 Weekly Recap & Free Low Drawdown Momentum Trade Ideas - sundaytimes.kr
What makes Cartesian Therapeutics Inc. stock price move sharplyInsider Selling & AI Enhanced Trading Alerts - Newser
Can Cartesian Therapeutics Inc. continue delivering strong returnsPost Earnings Surprise Movers - thegnnews.com
Cartesian Therapeutics Reports Positive Q2 2025 Earnings - TipRanks
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
Multi factor analysis applied to Cartesian Therapeutics Inc.Free AI Based High Gain Watchlist Scanner - Newser
Cartesian Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics 2025 Q2 Earnings Strong Net Income Amid Revenue Decline - AInvest
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Cartesian Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cartesian (RNAC) Q2 Revenue Drops 99% - sharewise.com
Cartesian Therapeutics reports second quarter 2025 financial results and provides business update - MarketScreener
Cartesian Therapeutics Inc Reports Q2 2025 EPS of $0.51, Surpassing Estimates, with Revenue at $298,000 - GuruFocus
Cartesian Therapeutics, Inc. SEC 10-Q Report - TradingView
Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday - Defense World
Bank of New York Mellon Corp Boosts Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Target Price from Analysts - Defense World
Design Therapeutics, Inc. shares rise 1.26% intraday as Cartesian Therapeutics reports strong clinical trial progress and global expansion. - AInvest
Cartesian Therapeutics Announces New Employment Inducement Grants - The Globe and Mail
Cartesian Therapeutics Grants Inducement Awards to New Employees. - AInvest
Cartesian Therapeutics Announces New Employee Incentive Grants - AInvest
Zacks.com featured highlights Amazon.com, Alphabet and Meta Platforms - The Globe and Mail
Candlestick Signal Suggests Reversal in Cartesian Therapeutics Inc.Expert Verified Stock Trade Ideas Backed by Data - metal.it
Cartesian Therapeutics Inc. Stock Analysis and ForecastBuild wealth faster with disciplined trading - Jammu Links News
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cartesian Therapeutics Inc Stock (RNAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):